Introduction: Oral antidiabetes medications, including dipeptidyl peptidase-4 inhibitors (DPP-4is) saxagliptin and sitagliptin, are used for the treatment of type 2 diabetes (T2D). The study objective was to compare all-cause and diabetes-related costs following initiation of saxagliptin or sitagliptin.
INTRODUCTION
The American Diabetes Association reports that between 2007 and 2012, the total cost of diabetes in the United States increased 41% from $174 billion (2007 USD) to $245 billion (2012 USD) [1] . Direct medical costs accounted for $176 billion [1] . The primary components of the costs were direct medical costs for inpatient care, prescription medications to treat diabetes-related complications, and antidiabetes therapies and supplies, responsible for 43%, 18%, and 12% of the $176 billion sum, respectively [1] . An additional $69 billion was attributed to lost productivity [1] . Compared with individuals without diabetes, patients diagnosed with diabetes have 2.3 times greater healthcare costs, averaging $13,741 annually compared with $5853 [1] . Therefore, an estimated $7888 in excess costs per year per person may be associated with diabetes [1] .
For patients with type 2 diabetes (T2D), the primary goal of treatment is to achieve and maintain glycemic control [2] , as poor glycemic control is associated with numerous microvascular and macrovascular complications including, but not limited to, diabetic nephropathy, retinopathy, coronary artery disease, and stroke [3] . For patients with T2D, standards of care recommend metformin first for appropriate patients in combination with dietary and lifestyle modifications, and if treatment failure occurs, the addition of a supplementary non-insulin agent such as a glucagon-like peptide-1 receptor agonist (GLP-1 RA), sodium glucose cotransporter 2 inhibitor (SGLT-2i), dipeptidyl peptidase-4 inhibitor (DPP-4i), thiazolidinedione (TZD), sulfonylurea (SU), or meglitinide (GLN) [2] [3] [4] .
In the United States, two commonly used DPP-4i medications are saxagliptin and sitagliptin. Compared with patients who initiated sitagliptin, saxagliptin initiators have been found to have better medication adherence and persistence [5] . Additionally, saxagliptin initiators were reported to have lower all-cause and diabetes-related medical costs over the 6 months following initiation [6] . Direct cost comparisons between patients treated with one of these two DPP-4i medications over longer periods of time are not available. This retrospective claims-based study sought to add to the body of available evidence by comparing the healthcare utilization and costs among patients with T2D who initiated saxagliptin to those who initiated sitagliptin in the 12 months following initiation.
METHODS

Study Design
This retrospective observational cohort study used administrative claims data to analyze the all-cause and diabetes-related healthcare resource utilization and costs for patients with T2D who initiated saxagliptin or sitagliptin between January 1, 2009, and January 31,
The patients included in this analysis
were a subset of a previously identified sample of patients with T2D [5] . Among these patients, healthcare resource utilization and costs were compared among saxagliptin initiators and sitagliptin initiators over the 12 months following DPP-4i initiation.
Data Sources
Two overlapped with index drug for at least 30 days in the first 45 days following index date; or (C) indexed on a fixed-dose metformin combination drug [5] . All other patients were considered to be on a monotherapy regimen [5] .
A full list of study covariates is included in Table 1 .
Statistical Analyses
Demographic, clinical, treatment regimen characteristics, and outcomes (Tables 1, 2, 3) were compared between the saxagliptin and sitagliptin cohorts using t tests for continuous variables and Chi-squared tests for categorical variables. Multivariable generalized linear models (GLMs) with a log link and gamma error distribution were used to compare costs among patients initiating saxagliptin and sitagliptin. A log link and gamma error distribution were used to handle the non-normal cost distributions. If the P value for the cost ratio of the cohort coefficient from the model was \0.05, the difference between the saxagliptin and sitagliptin cohorts was considered statistically significant. To present adjusted costs on the dollar scale, the recycled prediction method was used to generate predicted mean costs. In the recycled prediction method, mean costs are calculated for two pseudo-samples (one saxagliptin and one sitagliptin), the size of both pseudo-samples being the total number of patients. Each pseudo-sample is a combination of observed values for those patients who had the treatment concerned and predicted counterfactuals for those patients who had the other treatment.
Although the same methods of GLMs with log link and gamma error distribution, followed by use of the recycled prediction method to calculate adjusted costs on the dollar scale, were used to analyze all cost variables in separate models, the actual process followed was different for the inpatient cost variables and the others, i.e., total, medical, other outpatient medical and pharmacy costs. The reason for this difference is that a high percentage (approximately 90%) of inpatient costs were zero, i.e., the patient had no such costs, whereas for the other cost variables, hardly any patients had zero costs.
Therefore, for the inpatient costs only, a two-part modeling approach was used to estimate predicted probability of all-cause and diabetes-related inpatient admission and inpatient costs to account for patients with $0.
First, logistic regression models were fit to model the odds of inpatient admission and the estimates of coefficients from these models were used to generate predicted probabilities of inpatient admission. Second, GLMs with log link and gamma error distribution were fit to obtain predicted inpatient costs among patients with non-zero costs. To obtain average inpatient costs for each cohort, the predicted probability of inpatient admission was multiplied by the predicted costs. Bootstrapping, using 1000 resamples of the observed data, was used to generate 95% confidence intervals around probability of inpatient admission and average inpatient costs, these estimates of intervals and averages being taken from the bootstrapping distributions of the 1000 resamples.
For total, medical, other outpatient medical and pharmacy costs, only the GLMs with log link and gamma error distribution were fit (essentially discarding patients with zero costs), and bootstrapping was not used. The recycled prediction estimate of cost on the dollar scale for these outcomes was from the single analysis of the observed data. For these costs, the estimates of averages and 95% 
Compliance with Ethic Guidelines
The analyses presented are based on previously collected, de-identified data, and do not contain any new studies with human subjects performed by any of the authors. respectively, with no significant differences between the two cohorts. Overall, however, saxagliptin patients had a significantly greater number of unique ICD-9-CM diagnosis codes prior to the index date. A significantly larger proportion of saxagliptin initiators used metformin during the baseline period. There were no significant differences in total healthcare costs or diabetes medication costs during the baseline period, although total healthcare costs tended to be lower for saxagliptin initiators, on average. Regarding index regimen, a significantly smaller proportion of saxagliptin initiators had an index prescription that was a fixed-dose 
Healthcare Resource Utilization and Costs
Saxagliptin initiators tended to have lower unadjusted all-cause and diabetes-related medical costs than sitagliptin initiators in all service categories but most of the cost comparisons were not statistically significant ( Table 2) . Average outpatient pharmacy prescription costs were significantly higher for saxagliptin initiators. Healthcare utilization was similar between the two cohorts, although the proportion of patients with an all-cause inpatient admission was significantly smaller in the saxagliptin cohort.
Results
from multivariable models controlling for covariates and predicted costs are presented in Fig. 1 Fig. 1 All-cause and diabetes-related medical, pharmacy, and total costs over 12-month follow-up period. Asterisk a statistically significant difference (P\0.05) between saxagliptin initiators and sitagliptin initiators. CI confidence interval admission and costs are presented in Table S1 in the supplementary material. The predicted proportion of saxagliptin patients with an inpatient admission (11.0%) was significantly smaller than the predicted proportion of sitagliptin patients (12.5%, difference = 1.5%, 95% confidence interval -2.5%, -0.2%). There were no significant differences in predicted proportion of patients with a diabetes-related inpatient admission or predicted inpatients costs. Results for other outpatient medical costs models are presented in Table S2 
Adherence and Persistence to Initiated Medication during Follow-Up
As shown in Table 3 , over the 12-month follow-up period, the proportion of patients who were adherent was significantly greater in the saxagliptin cohort compared with the sitagliptin cohort in an unadjusted analysis. Similarly, a smaller proportion of saxagliptin initiators discontinued index drug during follow-up. The average number of index drug prescription fills was significantly higher for the saxagliptin cohort compared with the sitagliptin cohort ( Previous research has found that within the DPP-4i medication class, patients initiating saxagliptin had better adherence and persistence than patients who initiated sitagliptin [5] . Increasing adherence to antidiabetes medication has been correlated with increased glycemic control and decreased healthcare costs and resource utilization [10] [11] [12] .
A previous investigation by Kaltenboeck et al. [6] evaluated healthcare costs and utilization over 6 months following the initiation of saxagliptin, sitagliptin, or SU. Only unadjusted utilization results were presented [6] . Over the short follow-up period, significantly smaller proportions of saxagliptin initiators had an all-cause inpatient admission or an ER visit compared with sitagliptin initiators (7.2% vs. 10.6% and 14.1% vs.
17.5%, respectively) [6] . The same was true for diabetes-related inpatient admissions (4.0% vs. 6 .6%) and diabetes-related ER visits (5.7% vs. 7.3%) [6] . The saxagliptin cohort had a significantly greater proportion of patients with a diabetes-related outpatient visit (80.2% vs. 78.6%) [6] . Unadjusted mean all-cause and diabetes-related total costs were significantly lower for saxagliptin initiators than sitagliptin initiators ($7346 vs. $8797 and $2445 vs. $2828, respectively) [6] . Mean costs were significantly lower for all service categories except diabetes-related outpatient visits and diabetes-related prescription costs, although saxagliptin initiators tended to have lower costs for both [6] . The findings after adjusting for patient demographic and clinical characteristics were consistent [6] . Saxagliptin patients had significantly lower all-cause medical ($5073 vs. $5535, P\0.001) and total costs ($7802 vs. $8302, P\0.001) [6] . Additionally, compared with sitagliptin patients, saxagliptin patients had significantly lower diabetes-related medical ($1149 vs.
$1387, P\0.001) and total costs ($2510 vs.
$2772, P\0.001) [6] . This study has several limitations to acknowledge. First, administrative claims data are not collected for research purposes, as the diagnostic coding on administrative claims is recorded by physicians to support reimbursement. Diagnoses on claims may be coded incorrectly, or not at all, thereby potentially introducing measurement error with respect to variables that incorporated ICD-9-CM codes into their definitions. Similarly, prescriptions that were filled and did not generate an insurance claim were not captured in this analysis. Adherence and persistence were calculated using the service date and days supply information found on outpatient prescription drug claims and while it is assumed that the medication was taken as directed, skipped doses or discontinuation of the medication before the end of the current days supply could not be captured. Next, observational analyses may be subject to residual confounding even after multivariable adjustment, and causal inferences should be made cautiously. Lastly, study findings may not 
